Sildenafil is the active drug in prescription products approved for more than one clinical use. In current U.S. labeling, major sildenafil product contexts include treatment of erectile dysfunction and treatment of pulmonary arterial hypertension, with the exact indication determined by the specific product and label.
The active ingredient remains sildenafil across these contexts, but brand identity, formulation, approved population, strength framework and prescribing information can differ. Sildenafil should therefore not be treated as though every product containing the drug has one interchangeable indication.
This page maps the major approved-use contexts and explains how indication, brand and formulation relate to one another. Disease-specific treatment detail remains on the dedicated sildenafil for erectile dysfunction and sildenafil for pulmonary hypertension pages.
The two major labeled clinical contexts for sildenafil-containing products are erectile dysfunction and pulmonary arterial hypertension. These uses involve the same active drug but are represented by different product labels and clinical frameworks.
Sildenafil products labeled for erectile dysfunction are intended for the ED treatment context. Sildenafil products labeled for pulmonary arterial hypertension are intended for PAH, including specific adult and pediatric populations described in the applicable product labeling.
The important distinction is that an indication belongs to a particular approved product and label. The ingredient name alone does not establish that every sildenafil formulation or product is approved for every sildenafil-associated use.
| Use Context | General Labeled Role | Related Page |
|---|---|---|
| Erectile dysfunction | Treatment of erectile dysfunction in products carrying an ED indication. | Sildenafil for Erectile Dysfunction |
| Pulmonary arterial hypertension | Treatment of PAH in sildenafil products carrying the applicable pulmonary-hypertension indication. | Sildenafil for Pulmonary Hypertension |
Sildenafil identifies the active pharmaceutical ingredient. An indication describes the disease or clinical condition for which a particular medicine product is approved.
Those concepts operate at different levels. The same active molecule can appear in separate approved products whose indications, formulations and prescribing information are not identical.
This distinction explains why defining sildenafil only as an erectile-dysfunction drug or only as a pulmonary-hypertension drug is incomplete. The correct interpretation depends on the product being discussed.
| Concept | What It Identifies | Example |
|---|---|---|
| Active ingredient | The pharmacologically active drug | Sildenafil |
| Indication | The approved clinical use described in a product label | Erectile dysfunction or pulmonary arterial hypertension |
| Brand | The proprietary identity of a particular medicine product | Viagra or Revatio |
| Formulation | The physical dosage form in which the medicine is supplied | Tablet, oral suspension or injection depending on product |
Erectile dysfunction is one of the major approved uses of sildenafil. Viagra and multiple sildenafil tablet products are labeled for the treatment of erectile dysfunction.
In this context, sildenafil acts as a PDE5 inhibitor within the nitric oxide-cGMP signaling pathway involved in the physiological erectile response. The indication identifies the clinical use; it should not be confused with the underlying molecular mechanism.
The condition-specific role of sildenafil, including how the ED indication differs from other sildenafil product contexts, is covered on the sildenafil for erectile dysfunction page. Product identity for the branded ED context is covered separately on the sildenafil and Viagra page.
| Feature | Erectile Dysfunction Context |
|---|---|
| Active ingredient | Sildenafil |
| Drug class | PDE5 inhibitor |
| Major branded context | Viagra |
| Typical product form in this context | Oral tablet products |
| Indication | Treatment of erectile dysfunction |
| Detailed topic | Sildenafil and Erectile Dysfunction |
Sildenafil is also approved in specific products for pulmonary arterial hypertension. In current U.S. Revatio labeling, the indication specifically concerns pulmonary arterial hypertension classified as WHO Group I.
For adults, the labeled treatment context includes improving exercise ability and delaying clinical worsening. Current Revatio labeling also includes pediatric patients from 1 through 17 years of age with PAH, with the labeled outcome framework varying according to whether standardized exercise testing can be performed.
This is a separate clinical and regulatory context from sildenafil products labeled for erectile dysfunction. The broader condition-specific discussion belongs on the sildenafil for pulmonary hypertension page, while the Revatio product relationship is covered on the sildenafil and Revatio page.
| Feature | Pulmonary Arterial Hypertension Context |
|---|---|
| Active ingredient | Sildenafil |
| Drug class | PDE5 inhibitor |
| Major branded context | Revatio |
| PAH classification in U.S. Revatio labeling | WHO Group I |
| Adult labeled context | Treatment of PAH to improve exercise ability and delay clinical worsening |
| Pediatric labeled context | PAH treatment in patients 1 through 17 years old under the current Revatio label |
| Detailed topic | Sildenafil for Pulmonary Hypertension |
Brand names identify specific medicine products rather than new active ingredients. Viagra and Revatio both contain sildenafil, but their branded labels were developed for different clinical contexts.
Viagra is associated with the erectile-dysfunction indication, while Revatio is associated with pulmonary arterial hypertension. Their common active ingredient explains their shared core pharmacology, but it does not make their product labels interchangeable.
For a broader map of proprietary and generic naming, see the sildenafil brand names page.
| Brand | Active Drug | General U.S. Label Context | Related Page |
|---|---|---|---|
| Viagra | Sildenafil | Erectile dysfunction | Sildenafil and Viagra |
| Revatio | Sildenafil | Pulmonary arterial hypertension | Sildenafil and Revatio |
Viagra and Revatio share sildenafil as their active drug, but they are distinct medicine products with different approved-use contexts.
Their labeling differs in indication, formulation framework, strengths, administration information and other product-specific details. A shared active ingredient therefore does not make one branded product a substitute label for the other.
The brand-to-brand relationship is examined directly on the Viagra vs Revatio comparison page.
| Comparison Level | Viagra and Revatio |
|---|---|
| Active drug | Both contain sildenafil |
| Brand identity | Different |
| Primary labeled clinical context | Different |
| Formulation framework | Different |
| Product labeling | Different |
Sildenafil is available in more than one pharmaceutical dosage form, but formulation availability is tied to specific products and labeled clinical contexts.
In the branded U.S. context, Viagra is supplied as oral tablets for erectile dysfunction. Revatio labeling includes oral tablets, oral suspension and an intravenous injection for pulmonary arterial hypertension.
The presence of sildenafil in different dosage forms does not mean every formulation carries both indications. The complete dosage-form overview is covered on the sildenafil formulations page.
| Formulation | Product / Use Context | Related Page |
|---|---|---|
| Tablet | Used in sildenafil product contexts including ED and PAH, depending on the specific product label. | Sildenafil Tablets |
| Oral suspension | Included in the Revatio pulmonary arterial hypertension product framework. | Sildenafil Oral Suspension |
| Intravenous injection | Included in the Revatio pulmonary arterial hypertension product framework. | Sildenafil Injection |
Regulatory approval applies to a specific drug product and its labeling rather than to an active ingredient considered without product context.
The label identifies the indication, patient population, dosage form, administration framework, contraindications, warnings and other information governing that approved product.
This is why the statement that sildenafil is approved for a condition should always be interpreted alongside the particular product being discussed. Two products can contain the same active drug while carrying materially different labels.
| Label Element | What It Clarifies |
|---|---|
| Indication | The condition for which that product is approved |
| Population | The patient population included in the labeled indication |
| Dosage form | The pharmaceutical form covered by that product label |
| Administration information | How the specific labeled product is used |
| Contraindications and warnings | Important product-specific safety information |
The central molecular action comes from sildenafil itself. Sildenafil inhibits phosphodiesterase type 5, or PDE5, affecting the regulation of cyclic GMP signaling.
The core pharmacological target does not become a different target simply because the drug appears under a different indication. What changes is the physiological, clinical and product-label context in which that pharmacology is used.
Detailed molecular pharmacology belongs on the how sildenafil works page, with deeper pathway detail on the sildenafil PDE5 inhibition and NO-cGMP pathway pages.
| Level | Relationship Across Major Sildenafil Uses |
|---|---|
| Active ingredient | Shared: sildenafil |
| Primary pharmacological target | Shared: PDE5 |
| Physiological context | Different |
| Clinical indication | Different |
| Product label | Different |
An approved or labeled indication is a use included in the authorized prescribing information for a particular medicine product.
Medical literature can study or discuss sildenafil in additional clinical settings, but research discussion and off-label clinical use are not equivalent to a labeled indication.
This page therefore focuses on established product-label contexts rather than attempting to catalog experimental, historical or off-label uses. That keeps the meaning of 'sildenafil uses' tied to regulatory indication rather than every context in which sildenafil has ever been studied.
| Term | Meaning |
|---|---|
| Labeled indication | Clinical use included in the approved product labeling |
| Off-label use | Clinical use outside the approved indication or other labeled conditions of use |
| Research context | Use investigated scientifically without implying an approved indication |
Approval terminology should also be interpreted within a regulatory jurisdiction. The specific indication and wording discussed on this page primarily reflect current U.S. product-label context.
Products containing sildenafil can differ by manufacturer, approval pathway and labeling, and regulatory information can change over time. For that reason, the most precise question is not simply whether 'sildenafil' has an indication, but which sildenafil-containing product and label are being referenced.
The history and regulatory development of sildenafil products are covered separately on the sildenafil FDA approval page.
| Context | Why It Matters |
|---|---|
| Active drug | Identifies sildenafil as the pharmacological ingredient |
| Specific product | Identifies the medicine whose labeling is being considered |
| Regulatory jurisdiction | Determines which approval framework and label apply |
| Current labeling | Defines the approved indication and product-specific information at that time |
Sildenafil, Viagra, Revatio and the conditions associated with those products represent different levels of medicine information.
Sildenafil names the active drug. Viagra and Revatio identify branded products. Erectile dysfunction and pulmonary arterial hypertension identify clinical conditions appearing in different sildenafil product-label contexts.
Keeping these levels separate avoids treating a drug name, brand name, dosage form and indication as though they were interchangeable terms.
| Information Level | Example |
|---|---|
| Active drug | Sildenafil |
| Brand | Viagra or Revatio |
| Indication | Erectile dysfunction or pulmonary arterial hypertension |
| Formulation | Tablet, oral suspension or injection depending on product |
| Label | Product-specific regulatory prescribing information |
A use or indication answers what a specific medicine product is approved to treat. A mechanism explains how the active drug interacts with biological systems.
Knowing that sildenafil inhibits PDE5 does not by itself establish which product label, indication or patient population is being discussed.
For this reason, this page keeps approved-use mapping separate from the detailed pharmacodynamic explanation available on the sildenafil pharmacodynamics page.
| Question | Relevant Topic | Related Page |
|---|---|---|
| How does sildenafil act? | Mechanism of action | How Sildenafil Works |
| How does PDE5 inhibition fit into its pharmacology? | Pharmacodynamics | Sildenafil Pharmacodynamics |
| How do the brands relate to the active drug? | Brand identity | Sildenafil Brand Names |
| What pharmaceutical forms exist? | Formulations | Sildenafil Formulations |
An approved indication describes the regulatory use of a medicine product. It does not establish that the product is appropriate for every person who has that condition.
Individual prescribing requires consideration of factors beyond indication alone, including medical history, contraindications, interacting medicines and other clinical circumstances.
This page therefore explains labeled uses rather than selecting treatment or providing individualized prescribing advice. Safety topics are covered separately on the sildenafil contraindications, drug interactions and warnings pages.
| This Page Provides | This Page Does Not Provide |
|---|---|
| Approved-use overview | Individual treatment selection |
| Product and brand context | Personal prescribing recommendations |
| Formulation-to-indication context | Personalized dosing instructions |
| Regulatory terminology | Individual safety assessment |
A useful way to interpret sildenafil uses is to move from the active ingredient to the specific product, then identify the product's indication, formulation and regulatory label.
For disease-specific information, continue to the dedicated ED or PAH pages. For questions about product identity, brands and dosage forms, use the corresponding product-focused pages rather than assuming that one sildenafil product represents every other sildenafil context.
This structure keeps indication, mechanism, product identity and formulation separate while showing how they relate.
| Need | Start With |
|---|---|
| Erectile dysfunction use | Sildenafil for Erectile Dysfunction |
| Pulmonary arterial hypertension use | Sildenafil for Pulmonary Hypertension |
| Viagra product context | Sildenafil and Viagra |
| Revatio product context | Sildenafil and Revatio |
| Brand relationships | Sildenafil Brand Names |
| Dosage forms | Sildenafil Formulations |
| Regulatory history | Sildenafil FDA Approval |
| Mechanism | How Sildenafil Works |
Major approved sildenafil product contexts include treatment of erectile dysfunction and treatment of pulmonary arterial hypertension. The exact indication depends on the specific product and its regulatory label.
No. Sildenafil is also the active drug in products approved for pulmonary arterial hypertension.
Yes. Sildenafil-containing products such as Revatio are approved in the United States for pulmonary arterial hypertension, specifically PAH classified as WHO Group I under the applicable labeling.
The current U.S. Revatio label includes pediatric patients 1 through 17 years of age with pulmonary arterial hypertension. Other sildenafil product labels can differ, so the specific product labeling matters.
No. Both contain sildenafil, but Viagra is associated with the erectile-dysfunction indication while Revatio is associated with pulmonary arterial hypertension.
No. They share sildenafil as the active drug but have different brand identities, labeled indications, formulation frameworks and prescribing information.
No. The approved use depends on the specific product and label. Tablets can appear in different sildenafil product contexts, while oral suspension and intravenous injection are included in the Revatio PAH product framework.
The core pharmacological action remains PDE5 inhibition. What differs between indications is the physiological, clinical and product-label context in which that mechanism is used.
No. An approved use appears in the authorized labeling for a particular product, while an off-label use falls outside that approved indication or other labeled conditions of use.
No. An indication describes an approved product use but does not replace individual clinical assessment, including evaluation of contraindications, interactions and other relevant medical factors.